This approach aligns with several studies [24,25,26,27,28] that inform the question of the role of BRCA1/2 testing to guide the use of PARP inhibitors in the treatment of patients with human epidermal growth factor receptor 2 (HER2)–negative BC. This evidence concerns the gene BRCA1 and breast cancer.